IMMUNOCORE HLDGS ADS/1 Market Cap ($1.36 Billion)
Market Cap & Net Worth: IMMUNOCORE HLDGS ADS/1 (6YG)
IMMUNOCORE HLDGS ADS/1 market cap. IMMUNOCORE HLDGS ADS/1 (F:6YG) has a market capitalization of $1.36 Billion (€1.16 Billion) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #7369 globally and #1036 in its home market, demonstrating a -7.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IMMUNOCORE HLDGS ADS/1's stock price €24.80 by its total outstanding shares 50695078 (50.70 Million). Also see IMMUNOCORE HLDGS ADS/1 operating cash flow efficiency for how efficiently the company converts equity into cash flow.
IMMUNOCORE HLDGS ADS/1 Market Cap History (2021–2026)
IMMUNOCORE HLDGS ADS/1 market cap history from 2021 to 2026. Data shows change from $1.77 Billion to $1.58 Billion (-9.83% CAGR). Check 6YG live share price for real-time trading data and today's change.
IMMUNOCORE HLDGS ADS/1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IMMUNOCORE HLDGS ADS/1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 6YG net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.42x
IMMUNOCORE HLDGS ADS/1's market cap is 4.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $3.14 Billion | $174.36 Million | -$52.54 Million | 18.02x | N/A |
| 2023 | $3.62 Billion | $249.43 Million | -$55.29 Million | 14.49x | N/A |
| 2024 | $1.62 Billion | $310.20 Million | -$51.09 Million | 5.24x | N/A |
| 2025 | $1.77 Billion | $400.02 Million | -$35.51 Million | 4.42x | N/A |
Competitor Companies of 6YG by Market Capitalization
Companies near IMMUNOCORE HLDGS ADS/1 in the global market cap rankings as of November 3, 2026. Also see balance sheet size of IMMUNOCORE HLDGS ADS/1 for a full breakdown of the balance sheet.
Key companies related to IMMUNOCORE HLDGS ADS/1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of IMMUNOCORE HLDGS ADS/1 (2021–2026)
Market capitalization of IMMUNOCORE HLDGS ADS/1 from 2021 to today. Between 2021 and today, IMMUNOCORE HLDGS ADS/1's market cap moved from $1.77 Billion to $ 1.58 Billion, with a yearly change of -9.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.58 Billion | -10.74% |
| 2025 | €1.77 Billion | +8.76% |
| 2024 | €1.62 Billion | -55.08% |
| 2023 | €3.62 Billion | +15.09% |
| 2022 | €3.14 Billion | +77.85% |
| 2021 | €1.77 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of IMMUNOCORE HLDGS ADS/1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.36 Billion USD |
| MoneyControl | $1.36 Billion USD |
| MarketWatch | $1.36 Billion USD |
| marketcap.company | $1.36 Billion USD |
| Reuters | $1.36 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more